Vicor Technologies, Inc. Retains Cameron Associates for Investor Relations Services

March 23, 2009 |

4 min read

BOCA RATON, FL--(Marketwire - March 23, 2009) - Vicor Technologies, Inc. (OTCBB: VCRT) today announced that it has retained the services of Cameron Associates, Inc. to assist with its shareholder communications efforts. Cameron Associates is a leading investor relations and strategic advisory firm. Vicor Technologies is a development-stage biotechnology company focused on the commercialization of innovative non-invasive diagnostics for sudden cardiac death and trauma using its patented, proprietary PD2i algorithm.

Cameron will assist Vicor Technologies in broadening its financial market presence and establishing new relationships within the investment community. The firm has a wealth of experience representing fast growing emerging healthcare and technology companies.

“Vicor Technologies is making rapid progress in commercializing its innovative non-invasive diagnostics using its patented, proprietary PD2i algorithm,” stated David H. Fater, Vicor President and CEO. “An important priority going forward is to build a stronger relationship with and to transmit a deeper understanding of our business to a variety of constituencies in the capital markets, including institutional shareholders and analysts,” he continued. “We believe Cameron Associates, which has an excellent track record and a unique, compelling service model is an excellent fit for us. We look forward to benefiting from their insight into the marketplace and from their relationships within the capital markets,” Mr. Fater concluded.

About Cameron Associates, Inc.

Cameron Associates, founded in 1976, is a New York-based, full-service investor relations firm that currently advises over 35 public companies.

About Vicor Technologies, Inc.

Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i.) The PD2i is a deterministic, non-linear measure that analyzes electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations. Vicor currently has three products employing the PD2i algorithm. The PD2i Analyzer, now in commercialization, measures heart rate variability. The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA (Cardiac Analyzer), currently involved in multiple clinical trials, identifies patients at risk of suffering sudden cardiac death. Vicor anticipates additional applications employing the PD2i to enable early detection and risk stratification for a variety of other disorders and diseases.

Additional information is available at www.vicortech.com.

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements.

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS for military and civilian applications and the PD2i Cardiac Analyzer, our ability continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicar’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 09-06